Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Alvotech ( (ALVO) ).
On December 22, 2025, Alvotech reported that launches have begun across Europe for Gobivaz (golimumab), its biosimilar to Johnson & Johnson’s Simponi and the first Simponi biosimilar to reach any market globally. Commercialized exclusively in Europe by partner Advanz Pharma and backed in the UK by an NHS England tender award, Gobivaz is being introduced via prefilled syringe and autoinjector formats identical to the reference product, with availability in other EEA countries to roll out as national pricing and reimbursement decisions are completed; the product is manufactured at Alvotech’s Iceland facility and its approval followed extensive analytical, pre-clinical and clinical comparability studies, underscoring the company’s drive to expand access to lower-cost biologic treatments for immune-mediated inflammatory diseases.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech, founded by Robert Wessman and listed on Nasdaq, is a global biotechnology company focused solely on developing and manufacturing biosimilar medicines. Its portfolio includes approved biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, and it is advancing a pipeline of nine additional candidates targeting autoimmune, eye and bone disorders, respiratory disease and cancer. The company operates a fully integrated model with in-house capabilities and leverages a broad network of commercial partnerships to reach key markets across the United States, Europe, Asia, South America, Africa and the Middle East.
Average Trading Volume: 581,823
Technical Sentiment Signal: Sell
Current Market Cap: $1.43B
See more data about ALVO stock on TipRanks’ Stock Analysis page.